2 news items
Zomedica Announces First Quarter 2024 Financial Results: Revenue up 14% to $6.3 Million; 66% Gross Margin, and $91 Million in Liquidity
ZOM
9 May 24
as a percentage of total revenue to decrease throughout the balance of the year.Research and development expenses were $1.8 million, compared to $0.9
Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity
ZOM
1 Apr 24
was lower than our top line growth of 33%.Research and development expense for the year ended December 31, 2023, was $5.7 million, compared
- Prev
- 1
- Next